Anticoagulation during Extracorporeal Membrane Oxygenation (ECMO): A Selective Inhibitor of Activated Factor XII Compared to Heparin in an <i>Ex Vivo</i> Model.

Secondary Hemostasis Results Coagulation Tests Point-of-Care Tests: ACT and Rotational Thromboelastometry (ROTEM) There was a significant difference in ACT across treatment groups ( p = 0.008; −86.20; −143.10 to −29.26). From similar ACT at baseline, both groups showed an increasing trend over time with ACT in the IMB-F12 group reaching a plateau within 2–4 h ( Figure ).

also in 63,971 other papers

The IMB-F12 group showed a trend toward increased INTEM-CT compared to that of the heparin group.

also in 53,322 other papers